(19)
(11) EP 2 991 618 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.05.2019 Bulletin 2019/20

(45) Mention of the grant of the patent:
09.01.2019 Bulletin 2019/02

(21) Application number: 14721211.2

(22) Date of filing: 30.04.2014
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 9/08(2006.01)
A61K 47/24(2006.01)
 A61K 31/505(2006.01)
A61K 47/12(2006.01)
(86) International application number:
PCT/EP2014/001152
(87) International publication number:
WO 2014/177273 (06.11.2014 Gazette 2014/45)

(54)

STABLE HIGH STRENGTH PHARMACEUTICAL COMPOSITION OF LEVOLEUCOVORIN

STABILE HOCHDOSIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND LEVOLEUCOVORIN

COMPOSITION STABLE Ä UNE DOSE ÉLEVÉE CONTENANT LEVOLEUCOVORINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 30.04.2013 EP 13002298

(43) Date of publication of application:
09.03.2016 Bulletin 2016/10

(73) Proprietor: Aprofol AG
9050 Appenzell Steinegg (CH)

(72) Inventor:
  • ULMANN, Martin
    CH-8447 Dachsen (CH)

(74) Representative: Althaus, Roland 
Suisse Technology Partners AG Querstrasse 5
8212 Neuhausen am Rheinfall
8212 Neuhausen am Rheinfall (CH)


(56) References cited: : 
WO-A1-2010/043050
US-A- 4 931 441
 WO-A2-2004/112761
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).